Brief: Rosetta Genomics enters research collaboration using microrna biomarkers to predict response to leading immuno-oncology drug nivolumab in lung cancer patients
21/11/2016 13:00
Nov 21 (Reuters) - Rosetta Genomics Ltd ROSG.O :
* Rosetta genomics enters research collaboration using
microrna biomarkers to predict response to leading
immuno-oncology drug nivolumab in lung cancer patients
Source text for Eikon: ID:nBw3mVDhda
Further company coverage: ROSG.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Rosetta Genomics
See all newsBrief: Interpace Diagnostics Acquires Select Assets Of Rosetta Genomics Out Of Bankruptcy
Brief: Stockholders Approve Genoptix Acquisition Of Rosetta Genomics
Brief: Rosetta Genomics Announces Shareholder Approval Of Merger With Genoptix
Brief: Sabby Management Buys 105,361 ADR Shares Of Rosetta Genomics
Brief: Genoptix Announces Termination Of Merger Agreement With Rosetta Genomics